1	Characterization of Mycobacterium tuberculosis-specific Th22 cells and the effect of				
2	tuberculosis disease and HIV co-infection				
3					
4	Mohau S. Makatsa [*] , F. Millicent A. Omondi [*] , Rubina Bunjun [*] , Robert J. Wilkinson ^{†,‡,§,¶} Catherine				
5	Riou ^{*,†,‡,1} and Wendy A. Burgers ^{*,†,‡,1}				
6					
7	*Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, [†] Wellcome				
8	Centre for Infectious Diseases Research in Africa and [‡] Institute of Infectious Disease and				
9	Molecular Medicine, University of Cape Town, 7925, Cape Town, South Africa,				
10	$^{\$}$ Department of Medicine, Imperial College London, W21PG, London, UK and $^{\$}$ Francis Crick				
11	Institute Mill Hill laboratory, NW71AA, London, UK.				
12					
13	¹ C.R. and W.A.B. contributed equally to this work.				
14	Corresponding author: Wendy Burgers, Institute of Infectious Disease and Molecular Medicine,				
15	University of Cape Town, Falmouth Building, Room 3.36.1, Observatory 7925, South Africa.				
16	Phone: +27 21 406 6090, e-mail: wendy.burgers@uct.ac.za				
17					
18	Manuscript information:				
19	Running title: Mtb-specific Th22 cells in HIV-TB co-infection (41/60 characters)				
20	Abstract: 248 words; Figures: 6; Table: 1; Supplementary Figures: 2.				

21

22 ABSTRACT

23 The development of a highly effective tuberculosis (TB) vaccine is likely dependent on our 24 understanding of what constitutes a protective immune response to TB. Accumulating evidence 25 suggests that CD4+ T cells producing IL-22, a distinct subset termed 'Th22' cells, may contribute 26 to protective immunity to TB. Thus, we characterized Mycobacterium tuberculosis (Mtb)-specific 27 Th22 (and Th1 and Th17) cells in 72 individuals with latent tuberculosis infection (LTBI) or TB 28 disease, with and without human immunodeficiency virus (HIV)-1 infection. We investigated the 29 functional properties (IFN-y, IL-22 and IL-17 production), memory differentiation (CD45RA, 30 CD27 and CCR7) and activation profile (HLA-DR) of Mtb-specific CD4+ T cells. In HIV-31 uninfected individuals with LTBI, we detected abundant IFN- γ producing CD4+ T cells (median: 32 0.93%) and IL-22-producing CD4+ T cells (median: 0.46%) in response to Mtb. The frequency of 33 IL-17 producing CD4+ T cells was much lower, at a median of 0.06%. Consistent with previous 34 studies, IL-22 was produced by a distinct subset of CD4+ T cells and not co-expressed with IL-17. 35 Mtb-specific IL-22 responses were markedly reduced (median: 0.08%) in individuals with TB 36 disease and HIV co-infection compared to IFN-y responses. Mtb-specific Th22 cells exhibited a 37 distinct memory and activation phenotype compared to Th1 and Th17 cells. Furthermore, Mtb-38 specific IL-22 was produced by conventional CD4+ T cells that required T cell receptor (TCR) 39 engagement. In conclusion, we confirm that Th22 cells contribute substantially to the immune 40 response to TB. Depletion of Mtb-specific Th22 cells during HIV co-infection may contribute to 41 increased risk of TB disease.

42 INTRODUCTION

43 Tuberculosis (TB) is the leading cause of death from an infectious disease worldwide, with 10 44 million TB cases per year and 1.6 million deaths in 2018 (1). South Africa is one of the eight 45 countries that together account for two thirds of all TB cases globally (1). Moreover, approximately 46 one quarter of the world's population is latently infected with *Mycobacterium tuberculosis* (Mtb) 47 (1). In immunocompetent individuals, the risk of progression from infection to active TB disease is 48 2–10% in a lifetime, illustrating that the human immune system can control Mtb in most cases (2). 49 Bacillus Calmette-Guérin (BCG) is the only licensed TB vaccine and protects against disseminated 50 TB in children but provides variable protection against highly prevalent pulmonary tuberculosis 51 (PTB) in adults (3, 4). Therefore, there is an urgent need for new and effective TB vaccines, and 52 recent progress in clinical and pre-clinical trials have delivered promising results (5–7).

53

54 A better understanding of the immune responses required to control Mtb will aid the 55 development of improved vaccines against TB (8). It is well established that CD4+ T cells, 56 particularly Th1 cells producing the cytokines IFN- γ and TNF- α , are critical for immunity against 57 Mtb (8, 9). However, Th1 immunity alone is not sufficient, as IFN- γ has been reported to be a poor 58 correlate of BCG vaccination-induced protection against TB in mice (10, 11). Furthermore, IFN- γ -59 independent mechanisms of CD4+ T cell mediated control of Mtb infection have been documented 60 (12–14). Thus, other CD4+ T helper subsets beyond Th1 cells may be essential for protection 61 against TB.

62

63 There is growing interest in the cytokine IL-22 and its role in TB immunity. IL-22 belongs
64 to the IL-10 family of cytokines and its receptor is composed of two heterodimeric subunits, IL65 22R1 and IL-10R2 (15). IL-22 mainly targets non-hematopoietic cells, namely epithelial cells, and

66 fibroblasts in tissues (15), but expression of the IL-22 receptor has also been reported on 67 macrophages (16, 17). IL-22 promotes tissue proliferation, regeneration, and healing (15-20). It 68 induces the production of antimicrobial peptides and proteins such as β -defensions, the S100 family 69 of peptides, Reg3, calprotectin and calgranulin A (18–20). Furthermore, IL-22 signaling regulates 70 chemokine expression to orchestrate the recruitment of immune cell subsets to sites of infection (20, 71 21). During infection with Mtb, IL-22 was initially reported to be dispensable for Mtb control in 72 mouse models (22, 23). Recently, however, a protective role for IL-22 in TB immunity was 73 described in a murine model, where IL-22 deficient mice displayed greater bacterial burdens after 74 aerosol infection with a virulent clinical strain of Mtb, HN878 (17). In humans, soluble IL-22 has 75 been detected at sites of extra-pulmonary tuberculosis (24), and a higher concentration of IL-22 was 76 observed in bronchoalveolar lavage fluid (BALF) of individuals with active TB compared to 77 healthy donors (25). Moreover, IL-22 has been shown to inhibit intracellular M. tuberculosis 78 growth in macrophages (16), and a polymorphism in the IL-22 promoter has been linked to 79 increased TB risk (26).

80

81 IL-22 is produced by a variety of cells, including T cells (Th17, Th1 and $\gamma\delta$ T cells) and 82 innate cells (innate lymphoid cells (ILCs) and NK cells) (16, 27, 28). In humans, IL-22 is mainly 83 produced by a distinct subset of CD4+ T cells, named Th22 cells (29, 30). Our laboratory recently 84 showed that IL-22-producing CD4+ T cells contribute to the mycobacterial response during latent 85 TB infection (LTBI) (31). These mycobacteria-specific Th22 cells were depleted during HIV 86 infection to a similar extent as Th1 cells, emphasizing their potential importance in protective 87 immunity to TB in the context of HIV. In the present study, we further characterized Mtb-specific 88 Th22 cells during TB disease and HIV co-infection. This study investigated the contribution of 89 Th22 cells to TB immunity, characterized Th22 cells further to gain insights into their function, and examine the impact of TB disease and HIV infection on Th22 cells, in comparison to Th1 and Th17
cells. Our findings confirm that IL-22 is produced by CD4+ T cells in response to Mtb antigens, and
these Th22 cells contribute substantially to Mtb immune responses. Moreover, Mtb-specific Th22
cells were severely diminished in patients with both HIV infection and TB disease. Additionally,
we demonstrate for the first time that IL-22 production is dependent on TCR engagement but may
require alternative co-stimulatory molecules or antigen presenting cells.

96

97 MATERIAL AND METHODS

98 Study participants

99 Blood samples were collected from 72 individuals recruited from the Ubuntu Clinic, Khayelitsha, 100 Cape Town, South Africa. Participants were classified into four groups according to their HIV-1 101 infection status and whether they had latent TB infection (LTBI) or active TB disease (aTB): HIV-/ 102 LTBI (n = 19), HIV+/LTBI (n = 18), HIV-/aTB (n = 19), and HIV+/aTB (n = 16). The clinical 103 characteristics for each group are presented in Table 1. LTBI was diagnosed based on a positive 104 IFN-γ release assay (QuantiFERON®-TB Gold In-Tube), no symptoms of aTB and no detection of 105 Mtb in sputum by GeneXpert. Diagnosis of aTB was based on clinical symptoms and positive 106 sputum test (GeneXpert). All HIV-infected individuals were antiretroviral treatment (ART) naïve 107 and all TB cases were drug sensitive and TB treatment-naïve at the time of enrolment. In addition to 108 the patient cohort, healthy adult donors were recruited from the University of Cape Town for 109 selected experiments. All participants gave written, informed consent. These studies were approved 110 by the University of Cape Town, Faculty of Health Sciences Human Research Ethics Committee 111 (HREC 279/2012 and HREC 896/2014).

112

113 Blood collection and whole blood stimulation

114 Blood was collected in sodium heparin tubes and processed within 4 hours of collection. Whole 115 blood assays were performed according the protocol described previously (32). Briefly, 0.5 ml of 116 heparinized whole blood was stimulated with Mtb cell lysate (strain H37Rv, 10 µg/ml, BEI 117 Resources), a Mtb-specific peptide pool consisting of 17 and 16 peptides covering the entire ESAT-118 6 (early secretory antigenic target-6) and CFP-10 (culture filtrate protein-10), respectively (4 119 µg/ml), bacillus Calmette-Guerin (BCG) (MOI of 4, Mycobacterium bovis Danish strain 1331, SSI) 120 or gamma-irradiated Mtb whole cells (Strain H37Rv, 600 µg/ml, BEI Resources) at 37°C for a total 121 of 12 h in the presence of the co-stimulatory antibodies anti-CD28 and anti-CD49d (1 µg /ml each; 122 BD Biosciences). Unstimulated cells were incubated with co-stimulatory antibodies only. After 7 h, 123 Brefeldin A (10 µg/ml; Sigma-Aldrich) was added. Red blood cells were lysed with Alternative 124 Lysing Solution (ALS: 150 mM NH4Cl, 10 mM KHCO₃, 1 mM Na₄EDTA), and the cell pellet was 125 subsequently stained with LIVE/DEAD[™] Fixable Violet Stain (Molecular Probes) or LIVE/DEAD 126 Fixable Near-IR Stain (Invitrogen). Cells were then fixed using FACS lysing solution (BD 127 Biosciences) and cryopreserved in FCS containing 10% dimethyl sulfoxide (DMSO) for batch 128 staining. For lymphocyte-specific protein tyrosine kinase (Lck) inhibition, whole blood from 129 healthy individuals was incubated with increasing concentrations (1 μ M to 60 μ M) of Lck inhibitor 130 (7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine, Sigma) for 30 min 131 prior to cell stimulation.

132

133 Intracellular Cytokine Staining and Flow Cytometry

Cryopreserved cells were thawed, washed and then permeabilized with Perm/Wash buffer (BD
Biosciences). Cells were incubated at 4°C for 1 h with the following antibodies: CD19 Pacific Blue
(6D5; Biolegend), CD14 Pacific Blue (M5E2; Biolegend), CD3 BV650 (OKT3; BD Biosciences),
CD4 PerCP-Cy5.5 (L200; BD Biosciences), CD45RA BV570 (HI100; Biolegend), CD27 PE-Cy5

138 (1A4CD27; Beckman Coulter), CCR7 PECF594 (3D12; BD Biosciences), HLA-DR APC-Cv7 139 (L243; BD Biosciences), IFN-γ Alexa700 (B27; BD Biosciences), IL-17 Alexa 647 (N49-653; BD 140 Biosciences), IL-22 PE (22URTI; e-Bioscience). In order to investigate which T cells produce IL-141 22 and IFN-y, the following antibodies were used for surface and intracellular staining: CD3 BV650 142 (OKT3; BD Biosciences), CD4 ECD (T4; Beckman Coulter), CD8 QD705 (3B5; Life 143 Technologies), CD56 PE-Cy7 (NCAM 16.2; BD Biosciences), Pan γδ PE (IMMU510; Beckman 144 Coulter), CD161 Alexa 647 (HP-3G10; eBioscience), Va7.2 BV510 (3C10; Biolegend), IFN-y 145 Alexa700 (B27; BD Biosciences), IL-22 BV421 (22URTI; eBioscience). Stained cells were 146 acquired on a BD Fortessa and analyzed using FlowJo (v10, TreeStar). A positive cytokine 147 response was defined as at least twice the background cytokine response from unstimulated cells. 148 To define the phenotype of cytokine-producing cells, a cutoff of 20 cytokine events was used. The 149 gating strategy applied is presented in **Supplemental Figure S1**.

150

151 Determining the TCR Vβ repertoire of cytokine+ cells

The IOTest® Beta Mark TCR Vβ Repertoire Kit (Beckman Coulter) was used to determine the TCR Vβ repertoire of Mtb-specific IFN- γ or IL-22-producing CD4+ T cells. Briefly, cells from Mtb lysate- stimulated whole blood were stained with CD3 BV650 (OKT3; BD Biosciences), CD4 PerCP-Cy5.5 (L200; BD Biosciences), IFN- γ Alexa700 (B27; BD Biosciences), IL-22 APC (22JOP; eBioscience) and each of the eight vials containing mixtures of conjugated TCR Vβ antibodies corresponding to 24 different specificities.

158

159 Statistical analysis

All statistical tests were performed using Prism (v6; GraphPad). Nonparametric tests were used forall comparisons. The Kruskal-Wallis test with Dunn's Multiple Comparison test was used for

multiple comparisons and the Mann–Whitney U test and Wilcoxon matched pairs test were used for
unmatched and paired samples, respectively. A p value of < 0.05 was considered statistically
significant.

165

166 **RESULTS**

167 Characterization of CD4 Th22 cells in the immune response to Mtb in HIV-/LTBI individuals

A subset of CD4+ T cells that produces the cytokine IL-22 in response to mycobacterial antigen 168 169 stimulation has been described (29-31). We sought to further characterize Mtb-specific IL-22 170 production and define the relative contribution of IL-22 compared to more frequently measured 171 responses, namely IFN- γ and IL-17. We first compared the magnitude of Mtb-specific IL-22-172 producing CD4+ T cells to IFN- γ and IL-17 responses, in whole blood from healthy individuals 173 with latent Mtb infection (n = 19; Figure 1A). Mtb-specific CD4+ T cell responses (producing any 174 of the measured cytokines) were detected in all individuals (median: 1.34%, interquartile range 175 (IQR): 0.97-2.52). The highest frequency was observed for IFN-γ responses (median: 0.93%, IQR: 176 0.40-1.60). Although lower, the magnitude of IL-22+ Mtb-specific CD4+ T cells was not 177 significantly different from the IFN-y response (median: 0.46%, IQR: 0.22-0.96). In contrast, IL-17 178 producing CD4+ T cells were detectable at much lower frequencies (median: 0.06%, IQR: 0.04-179 0.11), ~16 to ~8 fold lower than IFN- γ (p < 0.0001) and IL-22 (p = 0.0002) responses, respectively 180 (Figure 1B). Using a Boolean gating strategy, we next assessed all possible cytokine combinations 181 to determine the co-expression profile of IFN- γ , IL-22 and IL-17 in Mtb-specific CD4+ T cells. 182 **Figure 1C** shows that the single IFN- γ response accounted for a median of 60% of the total Mtb 183 response, and single IL-22-producing cells contributed a median of 37% to Mtb response. Cytokine 184 co-expression was marginal, with only a small proportion of IFN- γ /IL-22 co-expressing cells observed (median: 3.6%, IQR: 2-6). Only three out of 19 individuals produced IL-17 alone that
contributed more than 5% to the total Mtb response (Figure 1C).

187 We next sought to determine whether similar cytokine profiles were generated in response 188 to different types of Mtb antigens, and thus compared blood stimulated with Mtb lysate to gamma-189 whole cell Mtb (gamma-irradiated) and live mycobacteria (M. bovis BCG), as well as Mtb peptides, 190 using an ESAT-6 and CFP-10 peptide pool. No differences in the magnitude of IL-22, IFN- γ or IL-191 17 responses were observed between the different "complex" mycobacterial antigens tested (i.e. 192 Mtb cell lysate, gamma-irradiated Mtb and BCG), using 5 donors with LTBI (Supplemental 193 Figure S2A&B). This indicates that lysed, live or dead mycobacteria can detect IL-22 responses. In 194 contrast, IL-22 production was barely detectable in response to Mtb peptide stimulation in 11 195 donors with LTBI (Supplemental Figure 2C). These data raised two questions, namely (i) whether 196 IL-22 production originates from unconventional T cells; or (ii) is the result of T cell receptor 197 (TCR)-independent bystander activation, rather than being induced by CD4+ T cells upon 198 engagement of cognate antigen presented to the TCR (33). A variety of immune cells have the 199 ability to produce IL-22 (34, 35). Thus to address the first question, we investigated IL-22 and IFN-200 γ production from a range of T cell subsets in whole blood, including mucosal-associated invariant 201 T (MAIT) cells, γδ T cells, Natural Killer T (NKT) cells, CD4+ T cells and CD8+ T cells. Samples 202 were gated on live lymphocytes that were CD3+, and then defined as NKT (CD56+), $\gamma\delta$ (CD56-203 $\gamma\delta$ TCR+), MAIT (CD56- $\gamma\delta$ TCR-V α 7.2+CD161+), CD4 (NKT- $\gamma\delta$ TCR-MAIT-CD8-CD4+) and 204 CD8 (NKT-γδTCR-MAIT-CD4-CD8+) T cells (Figure 2A). In 10 healthy donors tested for 205 cytokine responses, all cell subsets of interest produced IFN- γ when stimulated with Mtb lysate. In 206 contrast, in 7/10 donors, IL-22 was exclusively produced by CD4+ T cells, with only 3 donors 207 demonstrating a minor contribution of either MAIT or $\gamma\delta$ T cells to the total IL-22 response from 208 CD3+ cells (Figure 2B). Of note, the majority of MAIT and $\gamma\delta$ T cells were CD4- (data not shown), indicating that our gating strategy used in the previous experiments was not likely to have
included IL-22 from these T cell sources. Thus, conventional CD3+CD4+ T cells appear to be the
major source of IL-22 in response to Mtb antigens.

212 In order to determine whether IL-22 production was Mtb-specific (i.e. stimulated via 213 recognition of cognate antigen by the TCR) or due to a bystander effect of cytokine activation of 214 non-specific cells, we inhibited the TCR pathway by blocking Lck (a tyrosine kinase critical for 215 early propagation of TCR signalling), using increasing concentrations of the Lck inhibitor 7-216 cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine. Using whole blood from 217 five donors with LTBI, we found that as for IFN- γ , IL-22 production was suppressed upon Lck 218 inhibition in a dose-dependent manner. Interestingly, the ED₅₀ (efficient dose causing 50% of 219 maximum effect) for IL-22 inhibition was 2.6 times lower compared to that of IFN-y inhibition (7.5 220 μ M and 19.5 μ M, respectively; Figure 2C). These data demonstrate that IL-22 production from 221 CD4+ T cells is TCR-dependent.

222 Lastly, we compared the TCR^β repertoire of IL-22 and IFN-γ-producing CD4+ T cells in 223 blood from five donors with LTBI, using a commercial typing test. Of note, while the kit detects 24 224 out of 64 known TCR v\u03b3s, this represents up to 70% of the normal human TCR v\u03b3 repertoire. 225 **Figure 3A** shows representative flow cytometry plots of nine out of 24 TCR v β s measured. V β 226 repertoire coverage for Mtb-specific IL-22-producing CD4+ T cells was broad and comparable to 227 total CD4+ T cells, while slightly lower coverage was observed for Mtb-specific IFN-γ producing 228 CD4+ T cells (medians 62%, 61% and 40%, respectively). Two TCRs, vβ2 and vβ5.1, accounted 229 for more than 5% of the total v β repertoire for both Mtb-specific IL-22 and IFN- γ producing CD4+ 230 T cells (median: 13.6% and 10.4% for $v\beta 2$, 8.5% and 6.7% for $v\beta 5.1$, respectively), and were also 231 the most prevalent v β s observed for total CD4+ T cells (median: 10.0% for v β 2 and 7.2% for v β 5.1, 232 **Figure 3B**). Thus, TCR v β repertoire usage was similar between IL-22 and IFN- γ -producing CD4+

233 T cells.

Overall, these results show that IL-22 contributes to a sizeable portion of the Mtb response and these cells constitute a subset distinct from Th1 or Th17 cells. Moreover, Mtb-specific IL-22producing CD4+ T cells appear to be conventional CD4+ T cells and are dependent on TCR signaling for cytokine production.

238

239 Mtb-specific Th22 cells exhibit distinct memory and activation profiles compared to Th1 and 240 Th17 cells

241 To further describe the phenotypic characteristics of Mtb-specific Th22 cells and compare them to 242 Th1 and Th17 subsets, we defined their memory (CD45RA, CD27 and CCR7) and activation 243 profile (HLA-DR) in healthy individuals with latent Mtb infection. We focused our analysis on 244 IFN-γ single producing cells (Th1), IL-22 single producing cells (Th22) and IL-17 single producing 245 cells (Th17), since the proportion of cytokine co-expressing cells was negligible (Figure 1C). The 246 measurement of CD45RA, CD27 and CCR7 enabled the detection of five distinct memory subsets, 247 namely naïve (CD45RA+CD27+CCR7+), central memory (CM: CD45RA-CD27+CCR7+), 248 transitional memory (TM: CD45RA-CD27+CCR7-), effector memory (EM: CD45RA-CD27-249 CCR7-), and effector cells (Eff: CD45RA+CD27-CCR7-; (Figure 4A). The memory profile of 250 Mtb-specific CD4+ T cells varied depending on their Th polarization. Th1 cells were significantly 251 enriched in the EM phenotype compared to Th22 and Th17 cells (median: 50%, 32% and 19%, 252 respectively). Moreover, the Th22 subset was characterized by a low proportion of cells exhibiting 253 a TM phenotype compared to the Th1 or Th17 subsets (median: 6%, 17%, 18%, respectively; 254 Figure 4C).

When assessing the activation status of Mtb-specific CD4+ Th subsets (**Figure 4B**), we observed that Th22 cells were characterized by a significantly lower expression of HLA-DR compared to

both Th1 and Th17 cells (median 1.1%, compared to 7.3% and 9.3%, respectively; **Figure 4D**). The slightly increased frequency of HLA-DR-expressing Th22 cells observed during HIV infection, unlike Th1, merely mirrored background HIV-induced activation observed on total CD4+ T cells. It is plausible that other activation markers may be expressed on activated Th22 cells, and we have observed CD69 and CD25 upregulation on Th22 cells upon Mtb stimulation of blood from latently infected individuals (J. W. Milimu, R. Keeton, W. A. Burgers, unpublished).

Overall, these results indicate that Mtb-specific Th22 cells exhibit distinct memory and activationprofiles compared to Th1 and Th17 cells.

265

266 HIV infection and TB disease alter the distribution of Mtb-specific CD4+ Th subsets

267 To define the impact of HIV infection and TB disease on the distribution of Mtb-specific Th 268 subsets, we compared the magnitude of Th1, Th22 and Th17 cells in 72 participants classified into 269 four groups according to their HIV-1 and TB status: HIV-/LTBI (n = 19), HIV+/LTBI (n = 18), 270 HIV-/aTB (n = 19), and HIV+/aTB (n = 16). The clinical characteristics of each group are 271 summarized in Table 1. All participants were sampled prior to HIV and/or TB treatment. In 272 participants with LTBI, HIV infection led to a significant reduction (median ~3.6 fold) in the 273 frequency of Mtb-specific Th1 cells (median: 0.23% for HIV+ and 0.84% for HIV-; p = 0.026; 274 Figure 5A). While not statistically significant, the magnitude of the Mtb-specific Th22 response 275 was also lower in HIV-infected participants compared to HIV-uninfected subjects (median: 0.18% 276 and 0.45%, respectively). When assessing the effect of TB disease, we found that whilst TB disease 277 did not significantly alter the magnitude of Th1 or Th22 responses in HIV-uninfected individuals, in 278 HIV-infected persons the Mtb-specific Th profile was markedly distorted during TB compared to 279 LTBI (Figure 5A). Indeed, the magnitude of Th1 responses was significantly higher in aTB/HIV+ 280 individuals compared to LTBI/HIV+ participants (median: 1.21% vs 0.23%, respectively, p =

281 0.0005). In contrast, Mtb-specific Th22 cells were significantly lower in aTB/HIV+ compared to 282 LTBI/HIV+ and LTBI/HIV- participants (median: 0.08% vs 0.23% and 0.45%, p = 0.046 and p <283 0.0001, respectively). No differences were observed for Mtb-specific Th17 cells in all four clinical 284 groups.

285 To account for the significant variation in absolute CD4+ T cell counts between groups 286 (Table 1), the absolute number of Mtb-specific CD4+ T cells was calculated and compared between 287 each group. As expected, HIV co-infection resulted in reduced Mtb-specific Th1 absolute cell numbers regardless of TB status (median: 1.4 vs 6.5 cells/mm³ in LTBI and 2.2 vs 5.4 cells/mm³ in 288 289 aTB; Figure 5B). A comparable profile was observed for Th22 cells, but due to the decreased 290 frequency of Th22 cells in aTB/HIV+ compared to LTBI/HIV+ and low CD4 counts in the former 291 group, the absolute number of circulating Mtb-specific Th22 cells was markedly reduced in 292 aTB/HIV+ individuals compared to LTBI (median: 0.09 vs 1.02 cells/mm³, respectively, Figure 293 **5B**). Of note, for HIV-infected individuals, we found no relationship between the frequency of any 294 of the Th cytokine responses with absolute CD4 count or HIV viral load, regardless of TB status 295 (data not shown).

Next, we examined how HIV infection and active TB might alter the relative contribution of Th subsets to the total Mtb response. Whilst there were no significant differences in the contribution of Th1 and Th22 cells to the Mtb response in LTBI/HIV-, LTBI/HIV+ and aTB/HIV- groups (medians for Th1: 60%, 48% and 72%; and medians for Th22: 37%, 37% and 22%, respectively), in the aTB/HIV+ group, the Mtb-specific response consisted almost exclusively of Th1 cells (>90%), with Th22 cells representing less than 5% of the total Mtb response (**Figure 5C**).

302

303 TB disease and HIV co-infection differentially influence memory and activation profiles of Mtb304 specific CD4+ Th subsets

305 Lastly, we performed phenotypic characterization of Mtb-specific CD4 Th subsets during HIV 306 infection and TB disease. Comparing first the memory differentiation phenotype of Th subsets, we 307 showed that TB disease, characterized by active bacterial replication, irrespective of HIV co-308 infection, promotes the differentiation of Mtb-specific Th1 cells. The proportion of Th1 cells 309 exhibiting an EM phenotype was significantly higher in aTB compared to LTBI (69% vs 50% for 310 HIV-, p = 0.0295 and 77% vs 45% for HIV+, p = 0.0004; Figure 6A). In contrast, no alteration of 311 the memory differentiation phenotype of Th22 or Th17 cells was observed in aTB. We next 312 assessed the effect of HIV infection and aTB on the activation profile of Mtb-specific CD4+ Th 313 subsets. As previously described (36), irrespective of HIV infection, Mtb-specific Th1 cells in aTB 314 were characterized by significantly higher expression of HLA-DR when compared to persons with 315 LTBI (median: 45% vs 7%, respectively for HIV-, p = 0.0004 and 60% vs 8% for HIV+, p =316 0.0009). However, aTB did not induce any significant changes in HLA-DR expression in Th22 or 317 Th17 cells (Figure 6B).

These data confirm that Mtb replication during TB disease influences the memory differentiation and activation of Mtb-specific Th1 cells. In contrast, TB disease does not alter the memory or activation profile of Mtb-specific Th22 cells, indicating that TB differentially modulates Mtb-specific Th1 and Th22 cells.

322

323 **DISCUSSION**

The importance of CD4+ Th1 (IFN- γ) and Th17 (IL-17) responses in protective immunity to *M. tuberculosis* is well established (9, 37). The emerging role of IL-22 and Th22 cells in TB immunity is less well studied, and we sought to address this knowledge gap. To better understand the contribution of Th22 cells to Mtb immune responses, we examined the dynamics of this subset in the context of TB disease and/or HIV infection by comparing the magnitude, differentiation and activation profiles of CD4+ T cells producing IFN- γ , IL-22 and IL-17. We confirm and extend our previous observations from latent Mtb infection (31), demonstrating that distinct, Mtb-specific IL-22-producing CD4+ T cells contribute a substantial portion to the total CD4+ T cell response to Mtb in both latent infection and TB disease. Furthermore, Th22 cells display different memory and activation profiles compared to Th1 and Th17 cells, and Mtb-specific Th22 are severely reduced in blood during TB disease in the context of HIV co-infection.

335

336 We show that Mtb-specific Th22 cells make up nearly 40% of the total Mtb response 337 measured in both LTBI and in TB disease, with Th1 cells contributing 60% and Th17 cells less than 338 3% to the response. In some individuals, the Th22 response was 60-70% of the total CD4+ T cell 339 response measured. These data suggest that Th22 cells may contribute to TB immunity. Indeed, IL-340 22 was recently found to play a protective role against the hypervirulent clinical strain of Mtb, 341 HN878, in a mouse model (17). In this model, an indirect mechanism of Mtb control was reported, 342 where IL-22 acted on lung epithelial cells to induce secretion of antimicrobial proteins, as well as 343 the induction of chemokines that led to enhanced recruitment of macrophages (17). A direct effector 344 function has also been described; whilst IL-22 receptors are present primarily on non-hematopoietic 345 cells, there is mounting evidence that they may be expressed on macrophages (16, 17). IL-22 346 inhibited Mtb growth through induction of TNF- α to activate macrophages and enhance 347 phagolysosomal fusion in infected macrophages through calgranulin A expression (16, 17, 38). In 348 addition to these murine, non-human primate and in vitro models demonstrating a role for IL-22 in 349 Mtb control, a human genetic study described polymorphisms in the promoter region of IL-22 350 leading to decreased IL-22 production, that were associated with greater TB susceptibility (26).

351

352 IL-22 has been classified as a Th17 cytokine due to co-expression with IL-17 in mouse 353 studies and several shared functions between the two cytokines (39). Consistent with previous 354 studies (29, 31), our results showed that the vast majority of IL-22 is produced independently of IL-355 17 (and IFN- γ) in humans. This implies a distinct role for IL-22 in the immune response to Mtb 356 compared to IL-17 (40). Indeed, IL-22 was required for Mtb control at the chronic stage of 357 infection, while IL-17 was important in the acute stage of Mtb infection in the same mouse model 358 (17, 41). Although IL-22 and IL-17 have some overlapping functions, such as inducing 359 antimicrobial peptides, regulating chemokine expression and promoting tissue proliferation and 360 healing (17, 18, 39, 41), IL-22 may also mediate mycobacterial control by inducing TNF- α for 361 macrophage activation (16, 17), a function that is more commonly associated with IFN- γ (42). 362 Further studies are warranted to define the relative contribution and potential synergy of IL-22 with 363 IFN- γ and IL-17 in protective immunity to TB.

364

365 In accordance with previous data (25), we show that Mtb-specific Th22 responses in the 366 blood were 50% lower in individuals with TB compared to Mtb-exposed individuals. It is likely that 367 in the context of TB disease, Mtb-specific Th22 cells migrate to the lungs. This conjecture is based 368 on the fact that IL-22-producing cells have been detected in the lungs and granulomas of rhesus 369 monkeys with TB (43, 44), that soluble IL-22 has been found to be elevated at the site of disease 370 during both pulmonary and extra-pulmonary TB (24, 25), and also that IL-22-producing cells 371 express CCR6, which has shown to mediate T cell homing to mucosal tissues (31). Two TB 372 treatment studies further support this hypothesis; Suliman and colleagues found that patients with 373 LTBI who received isoniazid prophylactic treatment had increased frequencies of BCG-specific IL-374 22-secreting CD4+ T cells compared to pre-treatment frequencies (45). Furthermore, Zhang and 375 colleagues reported an increase in Mtb-specific soluble IL-22 in blood of TB patients at the 378

377

376

379 Consistent with our recent findings (31), HIV infection resulted in a lower frequency of Th1 380 and Th22 cells in Mtb-exposed individuals, and also those with active TB. The depletion of Th22 381 cells could be explained by the fact that the majority of Th22 cells express CCR6 (31), and CD4+ 382 CCR6+ cells display an increased permissiveness to HIV infection (47-49), are enriched in HIV 383 DNA (50), and appear to preferentially support HIV replication (51). Indeed, CD4+CCR6+ cells 384 have been shown to express high levels of the HIV co-receptors CCR5 and CXCR4, important for 385 viral entry, as well as integrin $\alpha 4\beta 7$, which has been associated with increased HIV susceptibility 386 (47, 48, 52). Furthermore, CCR6+ cells lack the ability to secrete β -chemokines, which may protect 387 against HIV in an autocrine manner (52). Thus, in the context of both TB disease and HIV 388 infection, the combined effect of cell depletion and cell migration is the likely cause of the 389 strikingly low IL-22 responses we observed in blood.

completion of their anti-TB treatment, compared to before treatment (46). These studies suggest

that reduction of antigen load at the site of disease led to recirculation of Th22 cells to blood.

390

391 A range of innate and adaptive immune cells have been reported to produce IL-22 (16, 27, 392 26). In our study, we found that the predominant source of T cell-derived IL-22 in response to Mtb 393 antigens was conventional CD4+ T cells, excluding MAIT, $\gamma\delta$ and iNKT cells. Interestingly, whilst 394 IL-22 responses were readily detectable upon stimulation with whole or lysed mycobacteria (i.e. 395 Mtb cell lysate, gamma-irradiated Mtb and BCG), Mtb peptides were not able to stimulate IL-22 396 responses, raising the question of whether IL-22 production is induced through bystander effects on 397 T cells from structural components present in these mycobacterial antigen preparations, thus leading 398 to cytokine production. We showed for the first time that IL-22 production is indeed mediated by 399 TCR engagement, as demonstrated by inhibition of TCR signaling and resultant abrogation of 400 cytokine production. Furthermore, IL-22-producing CD4+ T cells displayed similar V β repertoire 401 usage as IFN-y producing CD4+ T cells. These data underscore our assertion that these are 402 conventional CD4+ T cells; however, whilst, conventional, they may not be classically restricted 403 (i.e dependent on MHC). The lack of detectable IL-22 in response to peptide stimulation suggests 404 that induction of IL-22 may be via alternative antigen presentation mechanisms and/or additional 405 co-stimulation requirements (53). One possibility is that IL-22 might be induced by modified 406 peptide or non-peptide antigens, such as lipopeptides or lipids, and we are currently exploring this 407 hypothesis. There is evidence supporting the production of IL-22 by CD4+ T cells recognizing 408 CD1a (54, 55), and both CD1a and CD1c can present lipopeptide antigens to conventional T cells (56). Of note, group 1 CD1-restricted T cells specific for microbial lipid antigens display similar αβ 409 410 TCR usage to peptide-specific T cells (57).

411 In conclusion, we provide evidence that Th22 cells are a major component of the specific 412 adaptive immune response to Mtb during both infection and disease, and that these cells are reduced 413 in blood during HIV co-infection, building on previous work. We hypothesise that Th22 cells could 414 migrate to the lungs and expand for an effective secondary immune response to provide long-lasting 415 protection against TB. To further investigate the specific role of Th22 cells in TB, it will be of 416 interest to compare the profile of Th22 we observed in blood with the site of disease. The recent 417 outcomes of vaccine candidate M72/AS01E demonstrating 50% efficacy against TB (5) and 418 intravenous BCG vaccination showing sterilizing immunity in NHPs (7) provide an ideal setting to 419 assess the potential protective role of Mtb-specific Th22 cells.

420

421 ACKNOWLEDGMENTS

422 We thank the study participants for providing samples and for their time and commitment to the 423 study, and to the clinic staff at the Ubuntu HIV-TB clinic. We thank Dr Charlotte Schutz and Dr 424 Cari Stek for phlebotomy. We thank Tracey Müller for assistance with sample processing, and
425 Kathryn Norman for administrative assistance. The following reagents were obtained through BEI
426 Resources, NIAID, NIH: *Mycobacterium tuberculosis*, Strain H37Rv, Gamma-Irradiated Whole
427 Cells, NR-14819 and *Mycobacterium tuberculosis*, Strain H37Rv, Whole Cell Lysate, NR-14822.
428
429 CONTRIBUTIONS

- 430 MSM, RJW, CR and WAB designed the study; MSM, RB and FMAO performed the experiments;
- 431 MSM analyzed the data and wrote the paper. CR and WAB contributed to the data discussion and
- 432 writing the paper. All authors read and approved the final manuscript.

433 **REFERENCES**

434 1. World Health Organization (2019) Global TB Report 2019.

435 <u>https://www.who.int/tb/publications/global_report/en/</u>

- 436 2. O'Garra, A., P. S. Redford, F. W. McNab, C. I. Bloom, R. J. Wilkinson et al. (2013) The
- 437 immune response in tuberculosis. Annu. Rev. Immunol. 31: 475–527. DOI: 10.1146/annurev-
- 438 immunol-032712-095939
- 439 3. Fine, P. E. M. (1995) Variation in protection by BCG: implications of and for heterologous
- 440 immunity. *Lancet* 346: 1339–1345. DOI: 10.1016/s0140-6736(95)92348-9
- 441 4. Trunz, B. B., P. Fine, and C. Dye (2006) Effect of BCG vaccination on childhood tuberculous
- 442 meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-

443 effectiveness. *Lancet* 367: 1173–1180. DOI: 10.1016/S0140-6736(06)68507-3

- 444 5. Tait, D. R., M. Hatherill, O. Van Der Meeren, A. M. Ginsberg, E. Van Brakel et al. (2019) Final
- 445 Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N. Engl. J. Med. 381:2429-
- 446 39. DOI: 10.1056/NEJMoa1909953
- 447 6. Nemes, E., H. Geldenhuys, V. Rozot, K. T. Rutkowski, F. Ratangee et al. (2018) Prevention of
- 448 *M. tuberculosis* Infection with H4:IC31 Vaccine or BCG Revaccination. *N. Engl. J. Med.* 379:
- 449 138–149. DOI: 10.1056/NEJMoa1714021
- 450 7. Darrah, P. A., J. J. Zeppa, J. A. Hackney, M. H. I. Wadsworth, T. K. Hughes et al. (2019)
- 451 Prevention of tuberculosis in macaques after intravenous BCG immunization. *Nature* 577. DOI:
- 452 10.1038/s41586-019-1817-8.
- 453 8. Sakai, S., K. D. Mayer-Barber, and D. L. Barber (2014) Defining features of protective CD4 T
- 454 cell responses to *Mycobacterium tuberculosis*. *Curr. Opin. Immunol.* 29: 137–142. DOI:
- 455 10.1016/j.coi.2014.06.003
- 456 9. Jasenosky, L. D., T. J. Scriba, W. A. Hanekom, and A. E. Goldfeld (2015) T cells and adaptive

457 immunity to *Mycobacterium tuberculosis* in humans. *Immunol. Rev.* 264: 74–87. DOI:

458 10.1111/imr.12274

- 459 10. Mittrücker, H. W., U. Steinhoff, A. Köhler, M. Krause, D. Lazar et al. (2007) Poor correlation
- 460 between BCG vaccination-induced T cell responses and protection against tuberculosis. *Proc.*
- 461 *Natl. Acad. Sci. U. S. A.* 104: 12434–12439. DOI: 10.1073/pnas.0703510104
- 462 11. Majlessi, L., M. Simsova, Z. Jarvis, P. Brodin, M. J. Rojas et al. (2006) An increase in
- 463 antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not
- 464 enhance protection against tuberculosis. *Infect. Immun.* 74: 2128–2137. DOI:
- 465 10.1128/IAI.74.4.2128-2137.2006
- 466 12. Gallegos, A. M., J. W. J. van Heijst, M. Samstein, X. Su, E. G. Pamer et al. (2011) A gamma
- 467 interferon independent mechanism of CD4 T cell mediated control of *M. tuberculosis* infection

468 in vivo. *PLoS Pathog*. 7: e1002052. DOI: 10.1371/journal.ppat.1002052

- 469 13. Wozniak, T. M., B. M. Saunders, A. A. Ryan, and W. J. Britton (2010) Mycobacterium bovis
- 470 BCG-specific Th17 cells confer partial protection against *Mycobacterium tuberculosis* infection
- 471 in the absence of gamma interferon. *Infect. Immun.* 78: 4187–4194. DOI: 10.1128/IAI.01392-09
- 472 14. Lu, L. L., M. T. Smith, K. K. Q. Yu, C. Luedemann, T. J. Suscovich et al. (2019) IFN-γ-
- 473 independent immune markers of *Mycobacterium tuberculosis* exposure. *Nat. Med.* 25: 977–987.
- 474 DOI: 10.1038/s41591-019-0441-3
- 475 15. Dudakov, J. A., A. M. Hanash, and M. R. M. van den Brink (2015) Interleukin-22:
- 476 immunobiology and pathology. *Annu. Rev. Immunol.* 33: 747–785. DOI: 10.1146/annurev477 immunol-032414-112123
- 478 16. Dhiman, R., M. Indramohan, P. F. Barnes, R. C. Nayak, P. Paidipally et al. (2009) IL-22
- 479 produced by human NK cells inhibits growth of *Mycobacterium tuberculosis* by enhancing
- 480 phagolysosomal fusion. J. Immunol. 183: 6639–6645. DOI: 10.4049/jimmunol.0902587

- 481 17. Treerat, P., O. Prince, A. Cruz-lagunas, M. Munoz-Torrico, M. Salazar-Lezama et al. (2017)
- 482 Novel role for IL-22 in protection during chronic *Mycobacterium tuberculosis* HN878 infection.
- 483 *Mucosal Immunol.* 10:1069-1081. DOI: 10.1038/mi.2017.15
- 484 18. Moyat, M., H. Bouzourene, W. Ouyang, J. Iovanna, J. C. Renauld et al. (2017) IL-22-induced
- 485 antimicrobial peptides are key determinants of mucosal vaccine-induced protection against *H*.
- 486 *pylori* in mice. *Mucosal Immunol*. 10: 271–281. DOI: 10.1038/mi.2016.38
- 487 19. Tyler, C. J., N. E. McCarthy, J. O. Lindsay, A. J. Stagg, B. Moser et al. (2017) Antigen-
- 488 Presenting Human γδ T Cells Promote Intestinal CD4+ T Cell Expression of IL-22 and Mucosal
- 489 Release of Calprotectin. J. Immunol. 198: 3417–3425. DOI: 10.4049/jimmunol.1700003
- 490 20. Whittington, H. A., L. Armstrong, K. M. Uppington, and A. B. Millar (2004) Interleukin-22: A
- 491 potential immunomodulatory molecule in the lung. *Am. J. Respir. Cell Mol. Biol.* 31: 220–226.
- 492 DOI: 10.1165/rcmb.2003-0285OC
- 493 21. Aujla, S. J., Y. R. Chan, M. Zheng, M. Fei, D. J. Askew et al. (2008) IL-22 mediates mucosal
- 494 host defense against Gram-negative bacterial pneumonia. *Nat. Med.* 14:275-281. DOI:
- 495 10.1038/nm1710
- 496 22. Behrends, J., J. Renauld, S. Ehlers, and C. Ho (2013) IL-22 Is mainly produced by IFN-γ-
- 497 secreting cells but is dispensable for host protection against *Mycobacterium tuberculosis*
- 498 infection. *PLoS One* 8:e57379. DOI: 10.1371/journal.pone.0057379
- 499 23. Wilson, M. S., C. G. Feng, D. L. Barber, F. Yarovinsky, A. W. Cheever et al. (2010) Redundant
- and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J.
- 501 *Immunol.* 184: 4378–4390. DOI: 10.4049/jimmunol.0903416
- 502 24. Matthews, K., K. A. Wilkinson, B. Kalsdorf, T. Roberts, A. Diacon et al. (2011) Predominance
- 503 of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. *Tuberculosis*
- 504 91: 587–593. DOI: 10.1016/j.tube.2011.06.009

- 505 25. Scriba, T. J., B. Kalsdorf, D.A. Abrahams, F. Isaacs, J. Hofmeister et al (2008) Distinct, specific
- 506 IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial
- 507 immune response. J. Immunol. 180: 1962–1970. DOI: 10.4049/jimmunol.180.3.1962
- 508 26. Zhang, G., X. Chen, L. Chan, M. Zhang, B. Zhu et al. (2011) An SNP selection strategy
- identified IL-22 associating with susceptibility to tuberculosis in Chinese. *Sci. Rep.* 1: 20. DOI:
 10.1038/srep00020
- 511 27. Toussirot, É., C. Laheurte, B. Gaugler, D. Gabriel, and P. Saas (2018) Increased IL-22- and IL-

512 17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With

513 Ankylosing Spondylitis.. Front. Immunol. 9: 1610. DOI: 10.3389/fimmu.2018.01610

- 514 28. Cella, M., R. Gamini, C. Sécca, P. L. Collins, S. Zhao et al. (2019) Subsets of ILC3–ILC1-like
- 515 cells generate a diversity spectrum of innate lymphoid cells in human mucosal tissues. *Nat.*

516 *Immunol.* 20: 980–991. DOI: 10.1038/s41590-019-0425-y

- 517 29. Trifari, S., C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits (2009) dentification of a human
- 518 helper T cell population that has abundant production of interleukin 22 and is distinct from
- 519 T(H)-17, T(H)1 and T(H)2 cells. *Nat. Immunol.* 10: 864–871. DOI: 10.1038/ni.1770
- 520 30. Eyerich, S., K. Eyerich, D. Pennino, T. Carbone, F. Nasorri et al. (2009) Th22 cells represent a
- 521 distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest.
- 522 119: 3573–3585. DOI: 10.1172/JCI40202
- 523 31. Bunjun, R., F. M. A. Omondi, M. S. Makatsa, T. L. Müller, R. Keeton et al. Th22 cells are a
- 524 major contributor to the mycobacterial CD4 + T cell response and are depleted during HIV
- 525 infection. *Under revision, J. Immunol.*
- 526 32. Hanekom, W. A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins et al. (2004) Novel
- 527 application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell
- 528 frequency in field studies. J. Immunol. Methods 291: 185–195. DOI: 10.1016/j.jim.2004.06.010

- 529 33. Boyman, O (2010) Bystander activation of CD4+ T cells. *Eur. J. Immunol.* 40: 936–939. DOI
 530 10.1002/eji.201040466
- 531 34. Sonnenberg, G. F., L. a Fouser, and D. Artis (2011) Border patrol: regulation of immunity,
- 532 inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat. Immunol.* 12: 383–390.
- 533 DOI: 10.1038/ni.2025
- 35. Ronacher, K., R. Sinha, and M. Cestari (2018) IL-22: An Underestimated Player in Natural
 Resistance to Tuberculosis? *Front. Immunol.* 9:2209.. DOI: 10.3389/fimmu.2018.02209
- 536 36. Riou, C., N. Berkowitz, R. Goliath, W. A. Burgers, and R. J. Wilkinson (2017) Analysis of the
- 537 Phenotype of *Mycobacterium tuberculosis*-Specific CD4+ T Cells to Discriminate Latent from
- 538 Active Tuberculosis in HIV-Uninfected and HIV-Infected Individuals. *Front. Immunol.* 8: 968.
- 539 DOI: 10.3389/fimmu.2017.00968
- 540 37. Shen, H., and Z. W. Chen (2018) The crucial roles of Th17-related cytokines/signal pathways in
- 541 *M. tuberculosis* infection. *Cell. Mol. Immunol.* 15: 216–225. DOI: 10.1038/cmi.2017.128
- 542 38. Dhiman, R., S. Venkatasubramanian, P. Paidipally, P. F. Barnes, A. Tvinnereim et al. (2014)
- 543 Interleukin 22 inhibits intracellular growth of *Mycobacterium tuberculosis* by enhancing

544 calgranulin A expression. J. Infect. Dis. 209: 578–587. DOI: 10.1093/infdis/jit495

- 545 39. Liang, S. C., X.-Y. Tan, D. P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos et al. (2006)
- 546 Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance
- 547 expression of antimicrobial peptides. J. Exp. Med. 203: 2271–2279. DOI:
- 548 10.1084/jem.20061308
- 549 40. Ouyang, W., J. K. Kolls, and Y. Zheng (2008) The biological functions of T helper 17 cell
- effector cytokines in inflammation *Immunity* 28: 454–467. DOI: 10.1016/j.immuni.2008.03.004
- 41. Gopal, R., L. Monin, S. Slight, U. Uche, E. Blanchard et al. (2014) Unexpected role for IL-17
- in protective immunity against hypervirulent *Mycobacterium tuberculosis* HN878 infection.

- 553 *PLoS Pathog.* 10: e1004099. DOI: 10.1371/journal.ppat.1004099
- 42. Flynn, J. A. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart et al. (1993) An essential
- role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med.
- 556 178: 2249–2254. DOI: 10.1084/jem.178.6.2249
- 43. Qiu, L., D. Huang, and C. Chen (2008) Severe tuberculosis induces unbalanced up-regulation of
- 558 gene networks and overexpression of IL-22, MIP-1α, CCL27, IP-10, CCR4, CCR5, CXCR3,
- 559 PD1, PDL2, IL-3, IFN-β, TIM1, and TLR2 but low antigen-specific cellular responses. *J. Infect.*
- 560 *Dis.* 198: 1514–1519. DOI: 10.1086/592448
- 561 44. Yao, S., D. Huang, C. Y. Chen, L. Halliday, G. Zeng et al. (2010) Differentiation, distribution
- and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. *PLoS*
- 563 *Pathog.* 6: e1000789. DOI: 10.1371/journal.ppat.1000789
- 45. Suliman S., H. Geldenhuys, J. L. Johnson, J. E. Hughes, E. Smit et al. (2016) Bacillus Calmette-
- 565 Guérin (BCG) Revaccination of Adults with Latent *Mycobacterium tuberculosis* Infection
- 566 Induces Long-Lived BCG-Reactive NK Cell Responses. *J Immunol.* 197:1100-1110. DOI:
- 567 10.4049/jimmunol.1501996
- 568 46. Zhang, M., G. Zeng, Q. Yang, J. Zhang, X. Zhu et al. (2014) Anti-tuberculosis treatment
- 569 enhances the production of IL-22 through reducing the frequencies of regulatory B cells.
- 570 *Tuberculosis* 94: 238–244. DOI: 10.1016/j.tube.2013.12.003
- 571 47. Monteiro, P., A. Gosselin, V. S. Wacleche, M. El-Far, E. A. Said et al. (2011) Memory CCR6
- 572 + CD4 + T cells are preferential targets for productive HIV type 1 infection regardless of their
- 573 expression of integrin β7. *J. Immunol.* 186: 4618–4630. DOI: 10.4049/jimmunol.1004151
- 574 48. Alvarez, Y., M. Tuen, G. Shen, F. Nawaz, J. Arthos et al. (2013) Preferential HIV infection of
- 575 CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of
- 576 CCR5 ligands. J. Virol. 87: 10843–10854. DOI: 10.1128/JVI.01838-13

- 577 49. Gosselin, A., P. Monteiro, N. Chomont, F. Diaz-Griffero, E. A. Said et al. (2010) Peripheral
- 578 blood CCR4 + CCR6 + and CXCR3 + CCR6 + CD4 + T cells are highly permissive to HIV-1
- 579 infection. J. Immunol. 184: 1604–1616. DOI: 10.4049/jimmunol.0903058
- 580 50. Gosselin, A., T. R. W. Salinas, D. Planas, V. S. Wacleche, Y. Zhang et al. (2017) HIV persists
- in CCR6 + CD4 + T cells from colon and blood during antiretroviral therapy. *AIDS* 31: 35–48.
- 582 DOI: 10.1097/QAD.00000000001309
- 583 51. Planas, D., Y. Zhang, P. Monteiro, J. P. Goulet, A. Gosselin et al. (2017) HIV-1 selectively
- targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms. *JCI Insight* 2.
- 585 DOI: 10.1172/jci.insight.93230
- 586 52. Sivro, A., A. Schuetz, D. Sheward, V. Joag, S. Yegorov *et al.* (2018) Integrin α4β7 expression
- 587 on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes.
- 588 Sci. Transl. Med. 10. DOI: 10.1126/scitranslmed.aam6354
- 589 53. Magee, C. N., O. Boenisch, and N. Najafian (2012) The role of costimulatory molecules in
- 590 directing the functional differentiation of alloreactive T helper cells. *Am. J. Transplant.* 12:
- 591 2588–2600. DOI: 10.1111/j.1600-6143.2012.04180.x
- 54. De Jong, A., V. Peña-Cruz, T. Y. Cheng, R. A. Clark, I. Van Rhijn et al. (2010) CD1a-
- autoreactive T cells are a normal component of the human $\alpha\beta$ T cell repertoire. *Nat. Immunol.*
- 594 11: 1102–1109. DOI: 10.1038/ni.1956
- 55. Otsuka, Y., E. Watanabe, E. Shinya, S. Okura, H. Saeki et al. (2018) Differentiation of
- 596 Langerhans Cells from Monocytes and Their Specific Function in Inducing IL-22-Specific Th
- 597 Cells. J. Immunol. 201: 3006–3016. DOI: 10.4049/jimmunol.1701402
- 598 56. Siddiqui, S., L. Visvabharathy, and C. R. Wang (2015) Role of Group 1 CD1-Restricted T Cells
- in Infectious Disease. Front. Immunol. 6:337. DOI: 10.3389/fimmu.2015.00337
- 600 57. Grant, E. P., M. Degano, J. P. Rosat, S. Stenger, R. L. Modlin et al. (1999) Molecular

- 601 recognition of lipid antigens by T cell receptors. *J. Exp. Med.* 189: 195–205. DOI:
- 602 10.1084/jem.189.1.195
- 603
- 604

605 Footnotes:

606	This project is part of the EDCTP2 programme supported by the European Union (EU)'s Horizon
607	2020 programme (TMA2016SF-1535-CaTCH-22, to WAB). WAB was also funded by the
608	SAMRC, NRF SA (92755) and NHLS Trust (2016-2DEV04). Further funding came from the
609	National Institutes of Health, the Office of the Director (OD) (NIH, R21AI115977 to CR). CR is
610	supported by the EDCTP programme supported by the European Union's Horizon 2020 programme
611	(TMA2017SF-1951-TB-Spec, to CR). RJW is supported by the Wellcome Trust (203135 and
612	104803), NIH (U01 AI115940), the Francis Crick Institute (Cancer Research UK, MRC UK and
613	Wellcome FC0010218), and SAMRC (SHIP). The funders had no role in study design, data
614	collection and analysis, decision to publish, or preparation of the manuscript.
615	

Disclosure: The authors have no conflicts of interest.

618619 Table 1: Clinical characteristics of the four study groups.

· · · · · · · · · · · · · · · · · · ·	LT	LTBI		Active TB		
	HIV-	HIV+	HIV-	HIV+		
n	19	18	19	16		
CD4 count (cells/mm ³) ^a	923 [687-1051]	547 [463-626]	648 [593-778]	153 [75-207]		
Log10 HIV viral load (RNA copies/ml) ^a	n.a	4.61 [3.72-4.97]	n.a	5.06 [4.68-5.54]		
Age ^a	25 [19-31]	33 [29-38]	31 [26-40]	34 [29-46]		
Sex (F/M)	9/10	16/2	2/17	9/7		
0 ^a medians and [interquarti	ile ranges]. F: female	e; M: male, LTB	I: latent tubercul	osis infection. n.		
1 not applicable.	-					
2						
3						
5 FIGURE LEGENDS						
6						
7 Figure 1: Contribution	Figure 1: Contribution of IFN- γ , IL-22 and IL-17 to Mtb-specific CD4+ T cell responses in					
8 individuals with latent T	individuals with latent TB infection (LTBI). (A) Representative flow cytometry plots of IFN- γ					
9 IL-22 and IL-17 producti	IL-22 and IL-17 production after stimulation with Mtb lysate. NS: no stimulation. (B) Summary					
0 graph of the frequency of	graph of the frequency of cytokine responses. Statistical comparisons were performed using a one-					
1 way ANOVA Friedman t	way ANOVA Friedman test. **** $p < 0.0001$. (C) Proportion of different combinations of IFN-					
2 IL-22 and IL-17 in respon	IL-22 and IL-17 in response to Mtb stimulation. Medians and interquartile ranges are depicted.					
3						

634 Figure 2: IL-22 responses from different cell populations and the impact of TCR blocking on 635 **IFN-γ and IL-22 production.** (A) Representative flow cytometry plots showing the gating strategy 636 for NKT, $\gamma\delta$, MAIT, CD4+ and CD8+ T cells. The overlaid dots indicate IFN- γ (blue) or IL-22 637 (red) production from live CD3+ lymphocytes in response to Mtb lysate. (B) The frequencies of 638 each subset are indicated, as a percentage of total live CD3+ cells. (B) IFN- γ (blue) and IL-22 (red) 639 responses to Mtb lysate from NKT, $\gamma\delta$, MAIT, CD4+ and CD8+ T cells in healthy donors (n=10). 640 Each dot represents one individual. (C) Representative flow cytometry plots showing Mtb-specific 641 IFN-y and IL-22 responses in the presence of different concentrations of Lck inhibitor 7-642 Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine and summary graph (n =643 5). Medians and interquartile ranges are depicted. Vertical arrows show ED₅₀. A nonlinear 644 regression curve fit was used.

645

Figure 3: TCR Vβ repertoire of IFN-γ and IL-22-producing CD4+ T cells. (A) Representative flow cytometry plots showing staining of 9/24 Vβ receptors on total CD4+ T cells, IFN-γ and IL-22-producing CD4+ T cells. (B) Bar graph (each bar represent a donor) and (C) summary pie chart showing expression of 24 Vβ receptors by total CD4+ T cells, IFN-γ and IL-22-producing CD4+ T cells (n = 5). Means are depicted.

651

Figure 4: Comparison of the memory differentiation and activation profile of Mtb-specific
Th1, Th22 and Th17 cells in LTBI individuals. (A) Representative overlay plots showing
memory subsets in total CD4+ T cells (grey), IFN-γ+ (blue), IL-22+ (red) and IL-17+ (green) cells
in response to Mtb lysate. (Naive: CD45RA+CD27+CCR7+; central memory (CM): CD45RACD27+CCR7+; transitional memory (TM): CD45RA-CD27+CCR7-, effector memory (EM):

657 CD45RA-CD27-CCR7-and effector cells (Eff): CD45RA+CD27-CCR7-). (**B**) Representative 658 overlay plots of HLA-DR expression in total CD4+ T cells (grey), IFN- γ + (blue), IL-22+ (red) and 659 IL-17+ (green) cells in response to Mtb lysate. Summary graph (n=19) showing distribution of 660 memory subsets (**C**) and expression of HLA-DR (**D**) on IFN- γ , IL-22 and IL-17-producing CD4+ T 661 cells in individuals with LTBI in the absence of HIV infection. Medians and interquartile ranges are 662 depicted. Statistical comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * 663 p < 0.05, ** p < 0.01, *** p < 0.001, ****p < 0.0001.

664

665 Figure 5: Contribution of IFN-y, IL-22 and IL-17 to Mtb-specific CD4+ T cell responses and 666 the effect of HIV infection and active TB disease. (A) Frequency of Th1, Th22 and Th17 667 responses and (B) absolute number of Th1, Th22 and Th17 cells detected in response to Mtb lysate 668 in LTBI/HIV- (n = 19), aTB/HIV- (n = 19), LTBI/HIV+ (n = 18) and aTB/HIV+ (n = 16) 669 individuals. Bars represent the medians. (C) Distribution of Mtb-specific cytokine responses. Each 670 section of the pie chart represents median proportions of specific combinations of cytokines, as 671 indicated by the color at the bottom of the graph. The bars represent the median and interquartile 672 range. The dotted line is at 5%. Statistical comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * p < 0.05, ** p < 0.01, *** p < 0.001, ****p < 0.0001. 673

674

Figure 6: Memory and activation profile of Mtb-specific CD4+ T cells in individuals with distinct HIV and tuberculosis (TB) disease status. (A) Memory phenotype and (B) HLA-DR expression of IFN- γ , IL-22 and IL-17 producing CD4+ T cells in LTBI/HIV-, aTB/HIV-, LTBI/HIV+ and aTB/HIV+ groups. Red bars represent the medians. Statistical comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * p < 0.05, ** p < 0.01, ****p < 0.001, ****p < 0.0001. 681

682

683	memory profile and functional properties of CD4+ T cells. NS: non-stimulated.
684	
685	Supplemental Figure S2: Comparison of CD4+ T cell frequencies detected using Mtb lysate,
686	gamma-irradiated Mtb, and BCG. (A) Representative flow cytometry plots showing IFN- γ , IL-22

Supplemental Figure S1: Gating strategy. Gating strategy used to determine the phenotype,

687 and IL-17 responses after stimulation of blood from healthy donors with Mtb lysate, gamma-

688 irradiated Mtb, and BCG. (B) Comparison of the frequency of IFN-γ, IL-22 and IL-17 after

689 stimulation with different antigens (n=5). (C) Comparison of the frequency of IFN- γ , IL-22 and IL-

690 17 when stimulated with ESAT-6/CFP-10 (n=11). Red bars represent the medians. Statistical

691 comparisons were performed using a one-way ANOVA Friedman test. *** p < 0.001.

FIGURE 1 Makatsa *et al.*



FIGURE 2 Makatsa *et al.*





FIGURE 3 Makatsa et al.





FIGURE 5 Makatsa *et al.*





Supplemental Figure 1 Makatsa *et al.*



Gated on CD4+ cells





Supplemental Figure 2 Makatsa et al.

